An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cue Health to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
SAN DIEGO, Calif.--(BUSINESS WIRE)-- Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 4:00 p.m. Pacific Time at the Waldorf Astoria Monarch Beach Resort & Club.
A live audio webcast and replay of the presentation may be accessed for 180 days on the “Investor Relations” section of the company’s website at: https://cuehealth.com/.
About Cue Health
Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. The Cue Health platform offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point of care, as well as on-demand telehealth consultations and treatment options for a wide range of health and wellness needs. Cue’s customers include federal and state public sector agencies and the private sector, which includes healthcare providers, enterprises, and individual consumers. Cue’s COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription. Cue has since received Emergency Use Authorization from the FDA for its molecular mpox test at the point of care and, to expand its test menu, the company has a number of other submissions under review by the FDA. Cue, founded in 2010, owns over 100 patents and is headquartered in San Diego. For more information, please visit www.cuehealth.com.
cue, a revolutionary device for tracking health information at the molecular level. for the first time, consumers can track 5 key health and lifestyle indicators: inflammation, vitamin d, fertility, influenza, and testosterone in just minutes, at home. cue sends the data via bluetooth 4.0 to the user's smartphone, where the free cue app reveals the interplay of activity, food, and sleep shaping the user at a molecular level. by simply adding a noninvasive droplet of saliva, blood, or nasal swab, you can access deep information about your body only previously available from a lab -- on demand and on your schedule. interactive charts put you in touch with your health, making it easy to discover new trends, monitor your progress, and share it with the people who matter most. cue also features life feed, an incredible new smartphone-based way to visualize the daily effect of activity, food, and sleep on your molecular health. cue makes research-based recommendations for foods proven to sup